ТЕ БРОД ИНСТИТЬЮТ ИНК. (US);ТЕ ДЖЕНЕРАЛ ХОСПИТАЛ КОРПОРЕЙШН (US);ДАНА-ФАРБЕР КЭНСЕР ИНСТИТЬЮТ, ИНК. (US)
发明人:
ФРИТЧ Эдвард Ф. (US),ХАКОЭН Нир (US),РУНИ Майкл Стивен (US),ШУКЛА Сашет Ашок (US),У Кэтрин Дж. (US),БАЧИРЕДДИ Паван (US),СУНЬ Цзинь (US)
申请号：
RU2017144467
公开号：
RU2017144467A
申请日:
2016.05.20
申请国别(地区):
RU
年份:
2019
代理人:
摘要：
Disclosed herein in one aspect is a pharmaceutical composition comprising a plurality of neoantigenic peptides and a pharmaceutically acceptable carrier, each neoantigenic peptide comprising a tumor-specific neoepitope capable of binding to an HLA protein in a subject, each tumor-specific neoepitope comprising a tumor-specific mutation present in a tumor, wherein (a) the composition comprises neoantigenic peptides comprising tumor-specific mutations present in at least 1% of subjects in a population of subjects suffering from cancer； (b) the composition comprises neoantigenic peptides comprising tumor-specific neoepitopes which bind to HLA proteins present in at least 5% of subjects in the population； and (c) the composition comprises at least one neoantigenic peptide capable of eliciting an immune response against a tumor present in at least 5% of the subjects in the population of subjects suffering from cancer.
